Immunotherapy-Related Pancreatitis: A Case Series of 8 Patients from a High-Volume Oncology Centre
Abstract
Abstract Introduction: Immune checkpoint inhibitors (ICIs) may lead to immune-related adverse events (irAEs), including the rare complication of immune-related acute pancreatitis (irAP). Current knowledge about irAP is limited to case reports and retrospective studies. Case Presentations: We retrospectively reviewed 8 patients diagnosed with irAP at a high-volume tertiary cancer centre in Chile between 2021 and 2025. Data were collected on cancer type, immunotherapy regimen, symptoms, enzyme levels, imaging, and treatment. The irAP diagnosis was established according to the American Gastroenterological Association criteria. Adverse reactions were graded using CTCAE v5.0. Of the 8 included patients, 4 had melanoma, 2 had breast cancer, and 2 prostate cancer. Seven received PD-1/CTLA-4 combination therapy, and 1 received anti-PD-1 monotherapy. The median time to the irAP diagnosis was 5 months. Seven patients presented with gastrointestinal symptoms. Enzyme elevations and imaging findings were variable. All patients were treated with systemic corticosteroids, and 3 required hospitalisation. Four patients were rechallenged with ICIs. Other grade ≥2 irAEs were observed in 6 patients. No deaths were directly attributable to irAP. Conclusion: As demonstrated, these manifestations can diverge substantially from those of classical pancreatitis, so establishing an irAP diagnosis requires a comprehensive assessment. Corticosteroids are an effective treatment in most cases, and ICI…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 8 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.